IMP3 and PCNA Expression in Laryngeal Squamous Cell Carcinoma in Sohag Governorate

NCT05293327 | Unknown

• 1 other identifier: Soh-Med-22-03-01
• Study Type: observational
• Target: 70
• Locations: 1 country
• Sites: 1

Brief Summary

Laryngeal cancer is responsible for 2-5% of all new cancer cases worldwide. Squamous cell carcinoma of the larynx (LSCC) is the most common malignant tumor of the larynx, accounting for 85-90% of all laryngeal malignancies. Despite significant therapeutic developments in recent decades, increases in patients' 5-year survival rates are still minimal , which is likely due to late-stage diagnosis and other complex factors. Therefore, to improve the outcome, timely diagnosis, selection of the most appropriate therapy, and an adequate follow-up approach is needed. The insulin-like growth factor II m-RNA-binding protein 3 (IMP3) is a new biomarker that may be implicated in the carcinogenesis of various malignancies, including head and neck squamous cell carcinoma. IMP3 normally expressed in embryonic tissue but decreases after birth and is no longer detectable in adult tissue With the exception of a few tissues. As a result, IMP3 is expressed only in tumors and not in neighboring normal tissues. Proliferating Cell Nuclear Antigen (PCNA) is a nuclear protein that acts as a cell proliferation marker. In most forms of solid malignancies, such as colorectal cancer and breast cancer, PCNA is closely linked to prognosis and survival. In this study, hoping to improve diagnosis of LSCC and assess prognosis better by using both IMP3 and PCNA biomarkers. As IMP3 may have a role in cell growth and proliferation and PCNA is a marker of cell proliferation; studying the association between both markers in laryngeal carcinoma is recommended.

Conditions

Laryngeal Squamous Cell Carcinoma

Outcome Measures

Primary Outcomes (1)

• Diagnosis and prognosis of Laryngeal Squamous Cell Carcinoma

  Immunohistochemical Expression of IMP3 and PCNA in Laryngeal Squamous Cell Carcinoma

  One or two days after staining sections with the markers

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Blocks obtained from laryngeal squamous cell carcinoma tissue previously extracted from patients treated in Sohag University Hospital

You may qualify if:

• Laryngeal resection (total or partial laryngectomy) and biopsies.
• Complete clinical data.

You may not qualify if:

• Patients with recurrence of the primary tumor.
• Patients with a history of preoperative chemotherapy and/or radiotherapy.

Sponsors & Collaborators

• Sohag University: lead

Study Sites (1)

Faculty of Medicine, Sohag University

Sohag, 82511, Egypt

RECRUITING

MeSH Terms

Conditions

Squamous Cell Carcinoma of Head and Neck

Condition Hierarchy (Ancestors)

Carcinoma, Squamous Cell; Carcinoma; Neoplasms, Glandular and Epithelial; Neoplasms by Histologic Type; Neoplasms; Head and Neck Neoplasms; Neoplasms by Site

Study Officials

• Asmaa AM Abd El-latif

  Faculty of Medicine,Sohag University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Asmaa AM Abd El-latif

CONTACT

+201010444557; zonazszs@hotmail.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Lecturerof Pathology

Study Record Dates

• First Submitted: March 13, 2022
• First Posted: March 24, 2022
• Study Start: June 1, 2022
• Primary Completion: March 1, 2023
• Study Completion: June 1, 2023
• Last Updated: April 1, 2022

Record last verified: 2022-03

Locations

EG (1)